Brookline Avenue Innovations

Brookline Avenue Innovations is a Deerfield-affiliated private company created to manage and support translational therapeutics projects emerging from Beth Israel Deaconess Medical Center. The collaboration was launched by Beth Israel Deaconess Medical Center and Deerfield Management in 2022 to accelerate the discovery and development of novel therapeutics, with Deerfield committing up to $130 million over ten years plus scientific and operational support. Brookline Avenue Innovations appears to function primarily as a funding, project-management, and commercialization vehicle rather than as a single-asset biotech company. It supports BIDMC investigators across all therapeutic areas and may also provide additional capital to create spinout companies from projects with commercial potential. Deerfield materials indicate the broader development engine supporting these collaborations works across small molecules and biologics, and can help advance projects from discovery through preclinical proof of concept and into the clinic.